Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.8M | $51.9M | $62.6M | $94.1M | $137M | $220M | $332M | $344M |
| Revenue growth | — | 127.6% | 20.8% | 50.2% | 45.7% | 60.4% | 51.1% | 3.7% |
| Gross profit | $17.5M | $44.6M | $53.0M | — | — | — | — | — |
| Gross margin | 76.8% | 85.9% | 84.5% | — | — | — | — | — |
| Operating income | -$3.84M | $7.33M | -$6.54M | -$40.1M | -$72.9M | -$68.0M | $8.67M | -$42.8M |
| Operating margin | -16.8% | 14.1% | -10.4% | -42.6% | -53.2% | -30.9% | 2.6% | -12.4% |
| Net income | -$6.37M | $5.28M | -$10.3M | -$31.3M | -$67.1M | -$57.5M | $18.2M | -$24.2M |
| Net margin | -27.9% | 10.2% | -16.4% | -33.3% | -49.0% | -26.1% | 5.5% | -7.0% |
| EPS (diluted) | -$5.33 | -$0.21 | -$0.54 | -$1.24 | -$2.58 | -$2.14 | $0.62 | -$0.83 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.3M | $7.01M | $9.87M | -$19.0M | -$41.7M | -$5.63M | $64.9M | $64.3M |
| Capital expenditures | $277K | $937K | $4.75M | $3.48M | $5.63M | $13.6M | $28.3M | $36.0M |
| Free cash flow | -$12.6M | $6.08M | $5.11M | -$22.5M | -$47.3M | -$19.2M | $36.5M | $28.3M |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $4.48M | $98.8M | $410M | $330M | $123M | $98.8M | $120M | $117M |
| Total assets | $22.4M | $120M | $439M | $463M | $447M | $453M | $531M | $579M |
| Total liabilities | $32.5M | $34.6M | $23.6M | $50.8M | $48.2M | $62.1M | $75.4M | $108M |
| Long-term debt | $24.5M | $19.3M | $0.00 | — | — | $0.00 | $9.74M | $9.64M |
| Shareholders' equity | -$56.6M | $85.1M | $416M | $412M | $399M | $391M | $456M | $471M |
| Retained earnings | -$57.5M | -$52.2M | -$62.5M | -$93.8M | -$161M | -$218M | -$200M | -$224M |
| Shares (wtd avg diluted) | 1.91M | 8.66M | 18.9M | 25.1M | 26.1M | 26.8M | 29.3M | 29.0M |
Every figure is extracted from CASTLE BIOSCIENCES INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.